Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5 Pt 1
|
| pubmed:dateCreated |
1989-12-5
|
| pubmed:abstractText |
Parallel to the increased acceptance of intervention for acute myocardial infarction, there has been a decrease in financial resources and reimbursement. To ascertain the relative cost to benefit of intervention, we evaluated 78 matched pairs of acute myocardial infarction patients from a prospective data base of 507 consecutive patients presenting with infarction from May 1986 to July 1987. The pairs were matched for age (mean 61 years), sex (68% male), and infarct location (43% anterior). Intervention (thrombolytics and/or percutaneous transluminal coronary angioplasty [PTCA]) was only applied to patients at less than 6 hours from symptom onset. Nonintervention patients were subsequently considered for angiography and revascularization (PTCA, coronary artery bypass grafting [CABG]) based on clinical criteria. Clinical outcome was evaluated by in-hospital mortality and uncomplicated status (free of angina, heart failure, or arrhythmias) at 72 hours. Intervention was associated with decreased mortality (5.3% versus 13%, p = 0.16) and increased uncomplicated course (43% versus 19%, p less than 0.001) as compared with patients not receiving intervention. Hospital procedures for the intervention and nonintervention group were as follows: diagnostic cardiac catheterization (99% versus 51%); PTCA (60% versus 0%); and CABG (14% versus 19%), respectively. The mean cumulative hospital and professional charges were $31,684 for the intervention group and $29,022 for the nonintervention group (p = 0.50). In conclusion, despite the potential marked incremental expense of technology associated with intervention for acute myocardial infarction, this analysis demonstrates that benefit in clinical outcome can be derived without substantially increased costs.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0002-8703
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
118
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
878-82
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:2510487-Aged,
pubmed-meshheading:2510487-Angioplasty, Balloon, Coronary,
pubmed-meshheading:2510487-Cost-Benefit Analysis,
pubmed-meshheading:2510487-Costs and Cost Analysis,
pubmed-meshheading:2510487-Female,
pubmed-meshheading:2510487-Fibrinolytic Agents,
pubmed-meshheading:2510487-Heart Catheterization,
pubmed-meshheading:2510487-Hospitalization,
pubmed-meshheading:2510487-Humans,
pubmed-meshheading:2510487-Male,
pubmed-meshheading:2510487-Middle Aged,
pubmed-meshheading:2510487-Myocardial Infarction,
pubmed-meshheading:2510487-Myocardial Revascularization,
pubmed-meshheading:2510487-Prospective Studies
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
The cost:benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis.
|
| pubmed:affiliation |
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022.
|
| pubmed:publicationType |
Journal Article
|